Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07013838 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a 24-week, single-center, randomized, open-label trial conducted by Peking Union Medical College Hospital. The aim of this study is to assess the efficacy and safety of deucravacitinib in adult patients with relapsing TAK in comparison to patients treated with TNF inhibitor (TNFi), the most well-recognized therapeutic choice of non-glucocorticoid immunosuppressive for patients with relapsed or refractory TAK.
Trial Details
NCT Number NCT07013838
Lead Sponsor Chinese SLE Treatment And Research Group
Conditions
(from sponsor)		 Takayasu Arteritis (TAK)
Related terms Recurrence, Takayasu Arteritis
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov